Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + brentuximab vedotin response-adapted phase II trial in pediatric and young adult relapsed/refractory classic Hodgkin lymphoma
NL-OMON53072Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, brentuximab vedotin and bendamustine in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: 3-year event-free survival in low-risk group and Complete metabolic response before HDCT/ASCT in standard-risk group. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON53072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53072.